ArticlePakistan journal of medical sciences2025
Comparative analysis of Mycoplasma Pneumoniae and Drug-induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in Children.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare the differences between clinical characteristics, therapeutic management, and prognosis of mycoplasma pneumonia (MP) and drug-induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) in children. Methods: This was a retrospective study. The clinical data of SJS and TEN patients admitted to Hebei Children's Hospital from 2014-2024 were retrospectively analyzed and divided into the MP group and the drug group based on laboratory findings and the ALDEN algorithm for comparative study. Results: A total of 42 cases were included in the study. Among them, 20 cases were in the MP group and 22 cases were in the drug group. The median age of MP group was 108.0 (54.0, 129.0) months, which was greater than drug group with 42.0 (22.5, 75.0) months, and the difference was statistically significant (P < 0.05). Ten cases (50.0%) in the MP group had chest CT suggestive of consolidation of lung/pleural effusion, which was higher than the two cases (9.1%) in the drug group, with a statistically significant difference (P<0.05). Both groups were given systemic corticosteroids (Cs) treatment, and the proportion of children receiving Cs shock therapy combined with intravenous immunoglobulin (IVIG) in the MP group was significantly lower than that in the drug group, with a statistically significant difference (P<0.05). When SCORTEN score ≧3, the proportion of the MP group receiving Cs shock therapy and IVIG application increased. The median SCORTEN score in both groups was two, corresponding to a predicted mortality rate of 12.2%, whereas all children in the MP group survived and three died in the drug group, with an actual mortality rate of 13.6%. Conclusion: MP infection and drugs constitute the predominant triggers of SJS/TEN in children, with non-steroidal anti-inflammatory drugs (NSAIDs) and Chinese patent medicines (CPMs) as the main sensitizing drugs. For those with SCORTEN≦2 points, macrolides combined with conventional dose Cs may be the first-line treatment option for them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.